Chondrosarcoma in the United States (1973 to 2003): An analysis of 2890 cases from the SEER database

Angela Ylenia Giuffrida, Jorge E. Burgueno, Leonidas Koniaris, Juan C. Gutierrez, Robert Duncan, Sean P. Scully

Research output: Contribution to journalArticle

139 Citations (Scopus)

Abstract

Background: Current demographic, prognostic, and outcomes data on the diagnosis and treatment of chondrosarcoma have been based on case series reported by individual treatment centers. The SEER (Surveillance, Epidemiology and End Results) database is a validated national epidemiological surveillance system and cancer registry that has been used extensively to evaluate treatment outcomes in cases of malignancy. The purpose of the present study was to use this database to identify demographic and prognostic characteristics of chondrosarcoma and to describe the natural history following the treatment of this rare disease in the United States over the last thirty years. Methods: Two thousand eight hundred and ninety patients with chondrosarcoma were identified in the SEER database, and information regarding the demographic and clinical characteristics of the patients, the histological features and grade of the tumors, the location and size of the tumors, the surgical stage at the time of diagnosis, the use of surgery and radiation treatment, and survival were extracted. Results: Comparison of the overall and disease-specific survival rates revealed that patients who survived for ten years were more likely to die of events that were unrelated to chondrosarcoma. The disease-specific survival rate leveled off at ten years of follow-up. Univariate analysis revealed that female sex, a low histological grade, and local surgical stage were associated with a significant disease-specific survival benefit. An age of fifty years or less and an appendicular location of the tumor were associated with a significant overall survival benefit. On multivariate analysis, only grade and stage had significant association with disease-specific survival. On the basis of a comparison of survival rates according to the decade of diagnosis, it appears that there has been no significant improvement in survival over the last thirty years. Conclusions: Only grade and stage are independent prognostic factors for survival in cases of chondrosarcoma. Current treatment algorithms have not improved the survival rates of patients with chondrosarcoma over the past thirty years. Routine patient surveillance following treatment should be extended to ten years of follow-up. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.

Original languageEnglish (US)
Pages (from-to)1063-1072
Number of pages10
JournalJournal of Bone and Joint Surgery - Series A
Volume91
Issue number5
DOIs
StatePublished - May 1 2009
Externally publishedYes

Fingerprint

Chondrosarcoma
Epidemiology
Databases
Survival
Survival Rate
Demography
Neoplasms
Therapeutics
Rare Diseases
Natural History
Registries
Multivariate Analysis
Radiation

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Chondrosarcoma in the United States (1973 to 2003) : An analysis of 2890 cases from the SEER database. / Giuffrida, Angela Ylenia; Burgueno, Jorge E.; Koniaris, Leonidas; Gutierrez, Juan C.; Duncan, Robert; Scully, Sean P.

In: Journal of Bone and Joint Surgery - Series A, Vol. 91, No. 5, 01.05.2009, p. 1063-1072.

Research output: Contribution to journalArticle

Giuffrida, Angela Ylenia ; Burgueno, Jorge E. ; Koniaris, Leonidas ; Gutierrez, Juan C. ; Duncan, Robert ; Scully, Sean P. / Chondrosarcoma in the United States (1973 to 2003) : An analysis of 2890 cases from the SEER database. In: Journal of Bone and Joint Surgery - Series A. 2009 ; Vol. 91, No. 5. pp. 1063-1072.
@article{94a404318c294ba7ad37b9ea3d1d024f,
title = "Chondrosarcoma in the United States (1973 to 2003): An analysis of 2890 cases from the SEER database",
abstract = "Background: Current demographic, prognostic, and outcomes data on the diagnosis and treatment of chondrosarcoma have been based on case series reported by individual treatment centers. The SEER (Surveillance, Epidemiology and End Results) database is a validated national epidemiological surveillance system and cancer registry that has been used extensively to evaluate treatment outcomes in cases of malignancy. The purpose of the present study was to use this database to identify demographic and prognostic characteristics of chondrosarcoma and to describe the natural history following the treatment of this rare disease in the United States over the last thirty years. Methods: Two thousand eight hundred and ninety patients with chondrosarcoma were identified in the SEER database, and information regarding the demographic and clinical characteristics of the patients, the histological features and grade of the tumors, the location and size of the tumors, the surgical stage at the time of diagnosis, the use of surgery and radiation treatment, and survival were extracted. Results: Comparison of the overall and disease-specific survival rates revealed that patients who survived for ten years were more likely to die of events that were unrelated to chondrosarcoma. The disease-specific survival rate leveled off at ten years of follow-up. Univariate analysis revealed that female sex, a low histological grade, and local surgical stage were associated with a significant disease-specific survival benefit. An age of fifty years or less and an appendicular location of the tumor were associated with a significant overall survival benefit. On multivariate analysis, only grade and stage had significant association with disease-specific survival. On the basis of a comparison of survival rates according to the decade of diagnosis, it appears that there has been no significant improvement in survival over the last thirty years. Conclusions: Only grade and stage are independent prognostic factors for survival in cases of chondrosarcoma. Current treatment algorithms have not improved the survival rates of patients with chondrosarcoma over the past thirty years. Routine patient surveillance following treatment should be extended to ten years of follow-up. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.",
author = "Giuffrida, {Angela Ylenia} and Burgueno, {Jorge E.} and Leonidas Koniaris and Gutierrez, {Juan C.} and Robert Duncan and Scully, {Sean P.}",
year = "2009",
month = "5",
day = "1",
doi = "10.2106/JBJS.H.00416",
language = "English (US)",
volume = "91",
pages = "1063--1072",
journal = "Journal of Bone and Joint Surgery - Series A",
issn = "0021-9355",
publisher = "Journal of Bone and Joint Surgery Inc.",
number = "5",

}

TY - JOUR

T1 - Chondrosarcoma in the United States (1973 to 2003)

T2 - An analysis of 2890 cases from the SEER database

AU - Giuffrida, Angela Ylenia

AU - Burgueno, Jorge E.

AU - Koniaris, Leonidas

AU - Gutierrez, Juan C.

AU - Duncan, Robert

AU - Scully, Sean P.

PY - 2009/5/1

Y1 - 2009/5/1

N2 - Background: Current demographic, prognostic, and outcomes data on the diagnosis and treatment of chondrosarcoma have been based on case series reported by individual treatment centers. The SEER (Surveillance, Epidemiology and End Results) database is a validated national epidemiological surveillance system and cancer registry that has been used extensively to evaluate treatment outcomes in cases of malignancy. The purpose of the present study was to use this database to identify demographic and prognostic characteristics of chondrosarcoma and to describe the natural history following the treatment of this rare disease in the United States over the last thirty years. Methods: Two thousand eight hundred and ninety patients with chondrosarcoma were identified in the SEER database, and information regarding the demographic and clinical characteristics of the patients, the histological features and grade of the tumors, the location and size of the tumors, the surgical stage at the time of diagnosis, the use of surgery and radiation treatment, and survival were extracted. Results: Comparison of the overall and disease-specific survival rates revealed that patients who survived for ten years were more likely to die of events that were unrelated to chondrosarcoma. The disease-specific survival rate leveled off at ten years of follow-up. Univariate analysis revealed that female sex, a low histological grade, and local surgical stage were associated with a significant disease-specific survival benefit. An age of fifty years or less and an appendicular location of the tumor were associated with a significant overall survival benefit. On multivariate analysis, only grade and stage had significant association with disease-specific survival. On the basis of a comparison of survival rates according to the decade of diagnosis, it appears that there has been no significant improvement in survival over the last thirty years. Conclusions: Only grade and stage are independent prognostic factors for survival in cases of chondrosarcoma. Current treatment algorithms have not improved the survival rates of patients with chondrosarcoma over the past thirty years. Routine patient surveillance following treatment should be extended to ten years of follow-up. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.

AB - Background: Current demographic, prognostic, and outcomes data on the diagnosis and treatment of chondrosarcoma have been based on case series reported by individual treatment centers. The SEER (Surveillance, Epidemiology and End Results) database is a validated national epidemiological surveillance system and cancer registry that has been used extensively to evaluate treatment outcomes in cases of malignancy. The purpose of the present study was to use this database to identify demographic and prognostic characteristics of chondrosarcoma and to describe the natural history following the treatment of this rare disease in the United States over the last thirty years. Methods: Two thousand eight hundred and ninety patients with chondrosarcoma were identified in the SEER database, and information regarding the demographic and clinical characteristics of the patients, the histological features and grade of the tumors, the location and size of the tumors, the surgical stage at the time of diagnosis, the use of surgery and radiation treatment, and survival were extracted. Results: Comparison of the overall and disease-specific survival rates revealed that patients who survived for ten years were more likely to die of events that were unrelated to chondrosarcoma. The disease-specific survival rate leveled off at ten years of follow-up. Univariate analysis revealed that female sex, a low histological grade, and local surgical stage were associated with a significant disease-specific survival benefit. An age of fifty years or less and an appendicular location of the tumor were associated with a significant overall survival benefit. On multivariate analysis, only grade and stage had significant association with disease-specific survival. On the basis of a comparison of survival rates according to the decade of diagnosis, it appears that there has been no significant improvement in survival over the last thirty years. Conclusions: Only grade and stage are independent prognostic factors for survival in cases of chondrosarcoma. Current treatment algorithms have not improved the survival rates of patients with chondrosarcoma over the past thirty years. Routine patient surveillance following treatment should be extended to ten years of follow-up. Level of Evidence: Prognostic Level II. See Instructions to Authors for a complete description of levels of evidence.

UR - http://www.scopus.com/inward/record.url?scp=70350061991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70350061991&partnerID=8YFLogxK

U2 - 10.2106/JBJS.H.00416

DO - 10.2106/JBJS.H.00416

M3 - Article

C2 - 19411454

AN - SCOPUS:70350061991

VL - 91

SP - 1063

EP - 1072

JO - Journal of Bone and Joint Surgery - Series A

JF - Journal of Bone and Joint Surgery - Series A

SN - 0021-9355

IS - 5

ER -